1. Meteorin-like/Meteorin-β protects heart against cardiac dysfunction.
- Author
-
Rupérez C, Ferrer-Curriu G, Cervera-Barea A, Florit L, Guitart-Mampel M, Garrabou G, Zamora M, Crispi F, Fernandez-Solà J, Lupón J, Bayes-Genis A, Villarroya F, and Planavila A
- Subjects
- Animals, Animals, Newborn, Blood Pressure genetics, Blood Pressure physiology, Cardiomegaly physiopathology, Cardiotonic Agents metabolism, Cells, Cultured, Echocardiography, Gene Expression Regulation, Heart Failure physiopathology, Humans, Male, Mice, Inbred C57BL, Mice, Knockout, Muscle, Skeletal metabolism, Myocytes, Cardiac cytology, Myocytes, Cardiac metabolism, Nerve Growth Factors metabolism, PPAR alpha genetics, PPAR alpha metabolism, Mice, Cardiomegaly genetics, Disease Models, Animal, Heart Failure genetics, Nerve Growth Factors genetics
- Abstract
Meteorin-like/Meteorin-β (Metrnl/Metrnβ) is a secreted protein produced by skeletal muscle and adipose tissue that exerts metabolic actions that improve glucose metabolism. The role of Metrnβ in cardiac disease is completely unknown. Here, we show that Metrnβ-null mice exhibit asymmetrical cardiac hypertrophy, fibrosis, and enhanced signs of cardiac dysfunction in response to isoproterenol-induced cardiac hypertrophy and aging. Conversely, adeno-associated virus-mediated specific overexpression of Metrnβ in the heart prevents the development of cardiac remodeling. Furthermore, Metrnβ inhibits cardiac hypertrophy development in cardiomyocytes in vitro, indicating a direct effect on cardiac cells. Antibody-mediated blockage of Metrnβ in cardiomyocyte cell cultures indicated an autocrine action of Metrnβ on the heart, in addition to an endocrine action. Moreover, Metrnβ is highly produced in the heart, and analysis of circulating Metrnβ concentrations in a large cohort of patients reveals that it is a new biomarker of heart failure with an independent prognostic value., Competing Interests: Disclosures: A. Bayes-Genis reported personal fees from Abbott, personal fees from Astra Zeneca, personal fees from Novartis, personal fees from Vifor, personal fees from Boehringer-Ingelheim, other from Critical Diagnostics, and personal fees from Roche Diagnostics outside the submitted work. No other disclosures were reported., (© 2021 Rupérez et al.)
- Published
- 2021
- Full Text
- View/download PDF